In:
Current Drug Targets, Bentham Science Publishers Ltd., Vol. 22, No. 3 ( 2021-02-17), p. 296-309
Kurzfassung:
Leishmaniasis is a neglected tropical disease affecting more than 1.5 million people annually,
with an annual mortality of over 20.000. The drugs used for its treatment are toxic, expensive, require extended treatment times and present variable efficacy. The disease severity and therapy
limitations suggest the need for new antileishmanial agents. In this context, in order to identify new options for treatment, a number of studies based on nanotechnological strategies have been carried
out. Poloxamers are triblock copolymers very often utilized for nanotherapeutic solutions, resulting in products with better solubility, higher stability, superior therapeutic efficacy and less
toxicity. This review will discuss the physicochemical properties of the copolymers, as well as describe the use of poloxamers for the development of therapeutic formulations to treat leishmaniasis.
Materialart:
Online-Ressource
ISSN:
1389-4501
DOI:
10.2174/1389450121666201106145022
Sprache:
Englisch
Verlag:
Bentham Science Publishers Ltd.
Publikationsdatum:
2021
SSG:
15,3
Bookmarklink